|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Selling, general and administrative expenses | |||||
| Research and development costs | |||||
| Gain related to litigation settlement | |||||
| Loss (recovery) due to misappropriation of assets, net | |||||
| Goodwill impairment | |||||
| Other expense (income), net | |||||
| Income from operations | |||||
| Interest and other financial expense, net | |||||
| Reclassification of actuarial gains from AOCI | |||||
| Income (loss) before earnings in affiliated companies and income taxes | |||||
| Income tax expense | |||||
| Earnings in affiliated companies, net of tax | |||||
| Net income (loss) | |||||
| Weighted-average shares outstanding (in thousands): | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
| Earnings (loss) per share | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) |
Loading...
